Effects of taxol resistance gene 1 on the cisplatin response in gastric cancer

Duan,Shuquan; Yin,Jie; Bai,Zhigang; Zhang,Zhongtao

doi:10.3892/ol.2018.8390

Effects of taxol resistance gene 1 on the cisplatin response in gastric cancer

Authors:
- Shuquan Duan
- Jie Yin
- Zhigang Bai
- Zhongtao Zhang
View Affiliations

Affiliations: Department of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing Key Laboratory of Cancer Invasion and Metastasis Research and National Clinical Research Center for Digestive Diseases, Beijing 100050, P.R. China
Published online on: March 30, 2018 https://doi.org/10.3892/ol.2018.8390
Pages: 8287-8294
Copyright: © Duan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cisplatin is used to treat multiple types of solid tumor, including gastric cancer. Although cisplatin initially exhibits good efficacy, therapeutic failure often occurs owing to the development of chemoresistance. To the best of our knowledge, the underlying mechanism of cisplatin resistance remains unknown. The aim of the present study was to assess whether taxol resistance gene 1 (TXR1) has a role in cisplatin response in gastric cancer. The expression of TXR1 in fresh‑frozen tissues of patients with gastric cancer who were sensitive or resistance to cisplatin was assessed. The level of TXR1 expression was significantly higher in cisplatin‑resistant specimens than that in cisplatin‑sensitive specimens. Next, the gastric cancer SGC‑7901 cell line was exposed to cisplatin to establish a cisplatin‑resistance subline, termed SGC‑7901/DDP, which exhibited a 6‑fold increases in the level of resistance. TXR1 expression was elevated in SGC‑7901/DDP cells. Overexpression of TXR1 induced cisplatin resistance in SGC‑7901 cells. Downregulation of TXR1 reversed the drug resistance caused by elevation of TXR1 expression in SGC‑7901/DDP cells. Animal experiments proved the effect of TXR1 in inducing cisplatin resistance in vivo. Further investigation revealed that TXR1 regulated cisplatin resistance via apoptosis. In conclusion, TXR1 is worthy of further in‑depth study as a potential therapeutic target in patients with gastric cancer.

View Figures

View References

1	Kato M and Asaka M: Recent knowledge of the relationship between Helicobacter pylori and gastric cancer and recent progress of gastroendoscopic diagnosis and treatment for gastric cancer. Jpn J Clin Oncol. 40:828–837. 2010. View Article : Google Scholar : PubMed/NCBI
2	Ikeda F and Kiyohasa Y: The epidemiology of gastric cancer: The Hisayama Study. Fukuoka Igaku Zasshi. 106:195–201. 2015.(In Japanese). PubMed/NCBI
3	De Milito A and Fais S: Tumor acidity, chemoresistance and proton pump inhibitors. Future Oncol. 1:779–786. 2005. View Article : Google Scholar : PubMed/NCBI
4	Florea AM and Büsselberg D: Cisplatin as an anti-tumor drug: Cellular mechanisms of activity, drug resistance and induced side effects. Cancers (Basel). 3:1351–1371. 2011. View Article : Google Scholar : PubMed/NCBI
5	Siddik ZH: Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene. 22:7265–7279. 2003. View Article : Google Scholar : PubMed/NCBI
6	Bai ZG, Qu X, Han W, Ma XM, Zhao XM and Zhang ZT: Expression of taxol resistance gene 1 correlates with gastric cancer patient clinical outcome and induces taxol resistance. Mol Med Rep. 3:1071–1078. 2010.PubMed/NCBI
7	Zhang H, Qu X, Ma X, Wang T, Yang Y, Ge Z, Zhang Z, Bai Z, Gao Y, Yuan Z and Wang Z: TXR1 and TSP1 expression varies by the molecular subtypes of breast cancer patients who received previous docetaxel-based first-line chemotherapy. Exp Biol Med (Maywood). 241:1919–1923. 2016. View Article : Google Scholar : PubMed/NCBI
8	Papadaki C, Tsaroucha E, Kaklamanis L, Lagoudaki E, Trypaki M, Tryfonidis K, Mavroudis D, Stathopoulos E, Georgoulias V and Souglakos J: Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer. Br J Cancer. 104:316–323. 2011. View Article : Google Scholar : PubMed/NCBI
9	Bi W, Wang Y, Sun G, Zhang X, Wei Y, Li L and Wang X: Paclitaxel-resistant HeLa cells have up-regulated levels of reactive oxygen species and increased expression of taxol resistance gene 1. Pak J Pharm Sci. 27:871–878. 2014.PubMed/NCBI
10	Papadaki C, Mavroudis D, Trypaki M, Koutsopoulos A, Stathopoulos E, Hatzidaki D, Tsakalaki E, Georgoulias V and Souglakos J: Tumoral expression of TXR1 and TSP1 predicts overall survival of patients with lung adenocarcinoma treated with first-line docetaxel-gemcitabine regimen. Clin Cancer Res. 15:3827–3833. 2009. View Article : Google Scholar : PubMed/NCBI
11	Bi J, Bai Z, Ma X, Song J, Guo Y, Zhao J, Yi X, Han S and Zhang Z: Txr1: An important factor in oxaliplatin resistance in gastric cancer. Med Oncol. 31:8072014. View Article : Google Scholar : PubMed/NCBI
12	Liu L, Bai Z, Ma X, Wang T, Yang Y and Zhang Z: Effects of taxol resistance gene 1 expression on the chemosensitivity of SGC-7901 cells to oxaliplatin. Exp Ther Med. 11:846–852. 2016. View Article : Google Scholar : PubMed/NCBI
13	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
14	van Amerongen R and Berns A: TXR1-mediated thrombospondin repression: A novel mechanism of resistance to taxanes? Genes Dev. 20:1975–1981. 2006. View Article : Google Scholar : PubMed/NCBI
15	Songun I, Keizer HJ, Hermans J, Klementschitsch P, de Vries JE, Wils JA, van der Bijl J, van Krieken JH and van de Velde CJ: Chemotherapy for operable gastric cancer: Results of the Dutch randomised FAMTX trial. The Dutch Gastric Cancer Group (DGCG). Eur J Cancer. 35:558–562. 1999. View Article : Google Scholar : PubMed/NCBI
16	Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A and Fleig WE: Chemotherapy in advanced gastric cancer: A systematic review and meta-analysis based on aggregate data. J Clin Oncol. 24:2903–2909. 2006. View Article : Google Scholar : PubMed/NCBI
17	Tsuruo T, Naito M, Tomida A, Fujita N, Mashima T, Sakamoto H and Haga N: Molecular targeting therapy of cancer: Drug resistance, apoptosis and survival signal. Cancer Sci. 94:15–21. 2003. View Article : Google Scholar : PubMed/NCBI
18	Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M and Kroemer G: Molecular mechanisms of cisplatin resistance. Oncogene. 31:1869–1883. 2012. View Article : Google Scholar : PubMed/NCBI
19	Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N and Sarkar S: Drug resistance in cancer: An overview. Cancers (Basel). 6:1769–1792. 2014. View Article : Google Scholar : PubMed/NCBI
20	Rueff J and Rodrigues AS: Cancer drug resistance: A brief overview from a genetic viewpoint. Methods Mol Biol. 1395:1–18. 2016. View Article : Google Scholar : PubMed/NCBI
21	Wu Q, Yang Z, Nie Y, Shi Y and Fan D: Multi-drug resistance in cancer chemotherapeutics: Mechanisms and lab approaches. Cancer Lett. 347:159–166. 2014. View Article : Google Scholar : PubMed/NCBI
22	Colloca G, Venturino A and Checcaglini F: Second-line chemotherapy in metastatic docetaxel-resistant prostate cancer: A review. Med Oncol. 29:776–785. 2012. View Article : Google Scholar : PubMed/NCBI
23	Holohan C, Van Schaeybroeck S, Longley DB and Johnston PG: Cancer drug resistance: An evolving paradigm. Nat Rev Cancer. 13:714–726. 2013. View Article : Google Scholar : PubMed/NCBI
24	O'Neill CF, Ormerod MG, Robertson D, Titley JC, Cumber-Walsweer Y and Kelland LR: Apoptotic and non-apoptotic cell death induced by cis and trans analogues of a novel ammine(cyclohexylamine)dihydroxodichloroplatinum(IV) complex. Br J Cancer. 74:1037–1045. 1996. View Article : Google Scholar : PubMed/NCBI
25	Henkels KM and Turchi JJ: Induction of apoptosis in cisplatin-sensitive and -resistant human ovarian cancer cell lines. Cancer Res. 57:4488–4492. 1997.PubMed/NCBI
26	Ye D, Shuhendler AJ, Pandit P, Brewer KD, Tee SS, Cui L, Tikhomirov G, Rutt B and Rao J: Caspase-responsive smart gadolinium-based contrast agent for magnetic resonance imaging of drug-induced apoptosis. Chem Sci. 4:3845–3852. 2014. View Article : Google Scholar : PubMed/NCBI
27	Lih CJ, Wei W and Cohen SN: Txr1: A transcriptional regulator of thrombospondin-1 that modulates cellular sensitivity to taxanes. Genes Dev. 20:2082–2095. 2006. View Article : Google Scholar : PubMed/NCBI
28	Sid B, Sartelet H, Bellon G, El Btaouri H, Rath G, Delorme N, Haye B and Martiny L: Thrombospondin 1: A multifunctional protein implicated in the regulation of tumor growth. Crit Rev Oncol Hematol. 49:245–258. 2004. View Article : Google Scholar : PubMed/NCBI